Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
Status:
Completed
Trial end date:
2020-11-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist
ropinirole for the treatment of hyperprolactinemia in patients with idiopathic
hyperprolactinemia and prolactinomas.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Columbia University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)